Why is there a levothyroxine shortage in 2026?

Current levothyroxine procurement difficulty reflects three overlapping factors, not a single supply failure. First, the November 2024 Viatris/Mylan voluntary recall for potency failures removed significant generic supply from a market that had already consolidated around a small number of manufacturers. Second, FDA’s March 2026 risk-based enforcement action on unapproved animal-derived thyroid products has created incremental demand pressure on synthetic levothyroxine as some patients transition off desiccated thyroid extract products. Third, the generic levothyroxine market has fewer active manufacturers than it did a decade ago, which means any single facility disruption carries greater weight across the distribution chain. The result is not a physical absence of product in every market at once — it is unpredictable regional tightness at specific strengths, particularly at the highest-volume sizes (50, 75, 100 mcg), with longer reorder cycles and less buffer inventory across the distribution chain.

What is the difference between Synthroid and generic levothyroxine?

Synthroid (manufactured by AbbVie) is the originator brand-name levothyroxine. Generic levothyroxine products contain the same active ingredient — levothyroxine sodium — at FDA-approved doses and are rated AB (therapeutically equivalent to Synthroid) by the FDA, meaning they meet the FDA’s bioequivalence standards. The ATA, AACE, and Endocrine Society recommend that once a patient is stabilized on a specific product — whether Synthroid or a particular manufacturer’s generic — they remain on that product, because small differences in tablet formulation or excipients may affect absorption and TSH levels in sensitive patients. Wholesale acquisition cost of Synthroid is substantially higher than generics. For patients whose thyroid function is well-controlled on a generic, there is generally no clinical reason to switch to Synthroid. For patients already stabilized on Synthroid, switching to a generic requires TSH follow-up to confirm the patient remains in therapeutic range.

What manufacturers make levothyroxine in the United States?

The major FDA-approved manufacturers of levothyroxine sodium for the U.S. market include Mylan Pharmaceuticals/Viatris and several other generic manufacturers. Brand-name products are manufactured by AbbVie (Synthroid), Pfizer (Levoxyl), and IBSA Pharma (Tirosint capsule, Tirosint-SOL liquid); Jerome Stevens Pharmaceuticals manufactures Unithroid, distributed by Lannett. The generic market has consolidated in recent years, with fewer manufacturers carrying aggregate U.S. prescription volume. For a current list of FDA-approved manufacturers and their approved products, the FDA Orange Book (searchable by active ingredient) is the authoritative source.

Can my pharmacy substitute one manufacturer’s levothyroxine for another?

Technically yes — FDA-approved generic levothyroxine products with AB ratings are legally substitutable in most states unless the prescriber has written “dispense as written.” Clinically, the ATA/AACE/Endocrine Society joint guidance recommends against switching manufacturers on a stabilized patient without prescriber notification and TSH follow-up. Some state pharmacy boards go further: North Carolina requires documented prescriber notification and consent before substituting an NTI drug to a different manufacturer; Kentucky restricts generic substitution for NTI drugs. The safest practice at the dispensing level is to notify the prescriber when manufacturer supply for a stabilized patient changes at fill, document the notification, and flag any patient with a history of titration sensitivity for follow-up. This is both a risk management practice and a requirement in certain states.

How do I set par levels for levothyroxine in my pharmacy?

Start with your dispensing data. Pull 90 days of levothyroxine fills and build a strength distribution — what percentage of your fills are at each of the 12 strengths. Your par level for each strength should be 30 days of average demand plus a shortage buffer of 15–20%. Set your primary manufacturer par to that full number, and hold a secondary manufacturer supply at 30–50% of primary for your top three velocity strengths. Reorder triggers should be set conservatively: 14 days of remaining supply on your primary, 21 days on your secondary. Review your par levels quarterly — patient panels shift, and stocking patterns that drifted from the current mix are the most common cause of localized shortages we see in pharmacy audits. If your practice has endocrinology, bariatric, or thyroid cancer patients in meaningful volume, adjust your strength distribution and specialty product inventory (Tirosint, high-dose generics) accordingly.

What is Tirosint and when should I stock it?

Tirosint is an FDA-approved levothyroxine soft gel capsule manufactured by IBSA Pharma. Unlike conventional levothyroxine tablets, Tirosint capsules contain a minimal excipient load — no dyes, no lactose, no gluten — which reduces absorption interference from food, beverages, or other drugs. Tirosint-SOL is the liquid solution form of the same product, also FDA-approved, with a December 2023 label update allowing administration 15 minutes before breakfast and confirming no labeled interaction with proton pump inhibitors. Stock Tirosint capsules and Tirosint-SOL when your practice population includes post-bariatric surgery patients, patients with gastrointestinal conditions affecting absorption, lactose-intolerant patients who report inconsistent response to standard tablets, or patients on chronic PPI therapy with subtherapeutic TSH results on conventional levothyroxine. Demand for Tirosint has grown consistently as prescribers become more familiar with the product’s absorption profile. It is not a high-volume SKU in most practices, but stocking out on a patient dependent on it creates an acute clinical problem with no easy generic substitute.

Industry

Levothyroxine Procurement Guide: Multi-Manufacturer Sourcing, Par Levels, and DSCSA Compliance in 2026

June 11, 202614 minute read

Takeaways:

The November 2024 Viatris/Mylan potency recall and the March 2026 FDA action on unapproved animal-derived thyroid products are the two primary drivers of current levothyroxine procurement disruption.
Levothyroxine is formally designated a narrow-therapeutic-index (NTI) drug by the FDA, which means manufacturer substitutions require prescriber awareness and, in many cases, TSH follow-up — not just a swap.
Single-manufacturer sourcing is the primary procurement risk for levothyroxine. Multi-manufacturer sourcing across a primary and secondary generic, plus a branded bridge supply, is the current standard for shortage resilience.
Stocking should reflect your actual patient panel’s strength distribution, not historical reorder patterns. Most practices we audit have drifted from their actual mix.
DSCSA electronic traceability requirements are fully enforced for large dispensers as of November 2025. Compliance is not optional.
Certain state pharmacy boards — including North Carolina and Kentucky — have rules governing manufacturer substitution for NTI drugs. Verify your state’s requirements before switching a stabilized patient’s manufacturer mid-therapy.

Levothyroxine consistently ranks among the three most-prescribed drugs in the United States, accounting for tens of millions of dispensing events annually. In 2026, it is also one of the most procurement-intensive drugs to keep on the shelf.

Several pressures converged in quick succession. A major generic manufacturer initiated a voluntary recall for potency failures in late 2024. The FDA took formal action in early 2026 on unapproved animal-derived thyroid products, creating incremental demand pressure on synthetic levothyroxine supply. Manufacturer consolidation has narrowed the generic market. And the 12-strength stocking complexity that has always made this drug difficult to manage now has less buffer to absorb shocks.

The result is that pharmacies, endocrinology practices, primary care clinics, and specialty facilities are reordering levothyroxine more often, from more manufacturers, with less predictability.

This guide gives procurement leads a working framework: what changed, what to stock, how to source across manufacturers without compromising patient safety, and how to set par levels that can absorb the next shortage without disrupting active prescriptions.

If you would rather skip the audit:

Request a free supply audit through your USA MedPremium representative. A procurement specialist will return a multi-manufacturer stocking strategy mapped to your patient population within five business days.

What Changed in Levothyroxine Supply Between 2024 and 2026

Three discrete events reshaped the levothyroxine procurement landscape within approximately 18 months. Most practices are still adjusting to all three.

The Viatris/Mylan Recall

On November 18, 2024, Mylan Pharmaceuticals (a Viatris company) initiated a voluntary retail-level recall of multiple lots of levothyroxine sodium tablets. The recall covered multiple strengths distributed nationwide between August 2023 and November 2024. The basis was potency failures — lots that failed dissolution testing, with some recording subpotency and others superpotency outside acceptable limits. The action was a multi-event recall spanning all 11 tablet strengths from 25 to 200 mcg, entered into the FDA enforcement report in December 2024.

The FDA classified the action as a Class II recall, meaning the affected lots could cause temporary or medically reversible adverse health consequences. Viatris had been a preferred generic source for a number of large pharmacy benefit managers and health system formularies. The recall created an immediate demand shift toward substitute manufacturer supply that the remaining generic market absorbed unevenly.

FDA Action on Unapproved Animal-Derived Thyroid Products

On March 11, 2026, the FDA formally notified manufacturers, importers, and distributors of unapproved animal-derived thyroid medications of its intent to issue risk-based enforcement priority guidance. Draft compliance guidance is expected by August 2026. The FDA’s action covers desiccated thyroid extract products including Armour Thyroid, Nature-Throid, and NP Thyroid, among others. An estimated 1.5 million patients received prescriptions for these products in 2024.

This action is not a market withdrawal or immediate removal from shelves — it signals FDA’s enforcement prioritization as it moves toward requiring these products to obtain approved applications. The downstream procurement effect on synthetic levothyroxine is real: patients transitioning off animal-derived products move onto levothyroxine or brand-name synthetic alternatives, and that incremental demand compresses the supply buffer for generics during the transition period.

Manufacturer Consolidation

The generic levothyroxine market has contracted over the past several years as smaller manufacturers exited or reduced production. When a small number of generic manufacturers carry the load for a drug prescribed tens of millions of times annually, a single facility disruption — whether a recall, a quality hold, or a capacity constraint — ripples through the entire distribution chain.

The old procurement model of ordering from one or two preferred generic manufacturers on a monthly cycle does not absorb shocks of the scale seen in the 2024 Viatris recall. Facilities that had already built multi-manufacturer sourcing routed around the disruption. Those that had not absorbed the full impact.

A consolidated generic levothyroxine market funneling nationwide demand through a few manufacturers, creating a single-point-of-failure supply bottleneck — As the generic levothyroxine market consolidates, a single manufacturer disruption — a recall, quality hold, or capacity constraint — bottlenecks supply across the entire distribution chain.

Why Levothyroxine Is Uniquely Vulnerable to Procurement Disruption

Narrow Therapeutic Index Status

The FDA formally classifies levothyroxine sodium as a narrow-therapeutic-index (NTI) drug and has applied tighter bioequivalence standards to levothyroxine generics since 2012, requiring fully replicated crossover studies with tighter acceptance criteria than standard generics. At the same time, the FDA grants AB ratings to approved generics, meaning they are legally substitutable.

The tension between NTI designation and AB rating is a point of ongoing debate. The American Thyroid Association (ATA), American Association of Clinical Endocrinology (AACE), and the Endocrine Society issued a joint statement recommending that patients remain on the same brand or the same manufacturer’s generic product once they have been stabilized. Their position is that FDA’s bioequivalence methodology — conducted in healthy volunteers measuring T4 levels rather than TSH — may not capture clinically relevant differences in real patients managing hypothyroidism. The FDA’s own real-world data study found that patients who switched among generics maintained equivalent TSH control to non-switchers. FDA requires TSH monitoring after any manufacturer or product switch but does not mandate that patients stay on a single manufacturer.

For procurement purposes, the practical implication is the same regardless of where one stands on the clinical debate: any manufacturer substitution mid-therapy requires prescriber awareness and, in many cases, TSH follow-up scheduling. That makes levothyroxine shortages a clinical workflow disruption, not just a supply logistics problem.

Two Procurement Implications That Other Generics Do Not Share

Manufacturer substitution is not a clean fix. When the preferred generic is unavailable, dispensing a different manufacturer’s product without prescriber notification is both a clinical risk and, in certain states, a regulatory compliance issue. Procurement decisions on levothyroxine cannot be made in isolation from the clinical team.

Strength complexity is severe. Levothyroxine is prescribed in 12 FDA-approved strengths: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg. Each strength is individually dosed. A pharmacy that stocks the wrong distribution of strengths relative to its patient panel will exhaust high-frequency strengths while accumulating slow-moving inventory of less common ones. A 10 percent reduction in available supply at a high-volume strength — 50 or 75 mcg — cascades into refill delays within days.

Clinical Risks of Manufacturer Substitution

Levothyroxine’s NTI status means procurement decisions carry downstream patient safety consequences. The documented clinical risks associated with unmanaged manufacturer-to-manufacturer substitution include:

Subclinical hypothyroidism or hyperthyroidism in patients previously stabilized, resulting from small differences in absorbed dose
Cardiac events in elderly or comorbid patients — iatrogenic thyrotoxicosis from overtreatment is associated with cardiac arrhythmia risk
Pregnancy-related complications — TSH changes during pregnancy increase risk of miscarriage, preeclampsia, and gestational diabetes in patients dependent on precise levothyroxine dosing
Thyroid cancer surveillance disruption — patients on TSH-suppressive therapy after thyroidectomy require precise dosing to maintain suppression targets; any change in bioavailability may require retitration

Any time manufacturer supply changes for a stabilized patient, the dispensing facility needs to flag the change to the prescriber and confirm whether follow-up TSH testing is indicated. Facilities with a documented substitution protocol — one that triggers prescriber notification automatically when manufacturer source changes at fill — protect both patient outcomes and their own liability exposure.

The 12-Strength Stocking Challenge

The strength distribution of your active patient panel should drive your par levels, not historical reorder quantities. The typical velocity profile below is a starting point — calibrate it to your prescribing mix.

25 mcg: Pediatric, elderly, mild hypothyroid, dose initiation. Lower velocity in most adult practices; verify pediatric demand before scaling par.
50 mcg: Common adult initiation dose. Moderate to high velocity; reliable baseline demand.
75 mcg: Common adult maintenance. High velocity in most primary care and endocrinology practices.
88 mcg: Titration step between 75 and 100 mcg. Moderate velocity; rising as titration granularity increases.
100 mcg: Common adult maintenance. Highest or second-highest velocity in most primary care practices.
112 mcg: Common titration step. Moderate velocity.
125 mcg: Common adult maintenance. Moderate velocity.
137 mcg: Specialty titration step. Stock case-by-case; lower velocity in primary care.
150 mcg: Higher-dose maintenance. Moderate velocity in endocrinology settings.
175 mcg: Specialty titration step. Lower velocity; stock case-by-case.
200 mcg: High-dose maintenance; post-thyroidectomy. Stock for endocrinology and oncology referral practices.
300 mcg: Rare; thyroid cancer surveillance with high-dose suppression targets. Stock only for identified specialty patients.

The procurement question to ask every quarter is not “how much levothyroxine did we dispense last month” — it is “what is the strength distribution of our active patient panel, and does our inventory match that distribution within a reasonable tolerance.” Most practices we audit have stocking patterns that have drifted from their actual patient mix because they have been reordering historical par levels rather than reviewing them against current prescribing data.

Brand-Name Levothyroxine: Synthroid, Levoxyl, Tirosint, and Unithroid

Generic levothyroxine carries the large majority of U.S. prescription volume, but four brand-name products each hold a meaningful share and each carries distinct procurement considerations.

Synthroid (AbbVie)

The legacy brand-name levothyroxine, marketed in the United States by AbbVie. Synthroid commands the highest consumer search volume among levothyroxine products by a substantial margin, reflecting a large stabilized patient base that actively requests it and may not accept generic substitution easily. Synthroid is available across all 12 strengths and is widely distributed. Wholesale acquisition cost is meaningfully higher than generics. Practices serving cash-pay patients or patients on formularies that require brand-name dispensing should maintain Synthroid inventory at the top velocity strengths.

Levoxyl (Pfizer)

Pfizer has held the Levoxyl NDA since its acquisition of King Pharmaceuticals in 2011. Levoxyl has a narrower but consistent patient base. It serves as a clinically appropriate brand-name alternative when Synthroid is delayed or unavailable, and as a backup option when payer or patient preference requires a branded product. A 2026 sourcing review notes that Levoxyl availability has been constrained in certain markets — verify current supply status with your distributor before building Levoxyl into your primary brand sourcing plan.

Tirosint and Tirosint-SOL (IBSA Pharma)

Tirosint is an FDA-approved levothyroxine soft gel capsule manufactured by IBSA Pharma. Tirosint-SOL is the FDA-approved liquid solution formulation, approved December 2016. Consumer search demand for Tirosint has grown consistently as prescribers increasingly select it for patients with absorption concerns — lactose intolerance, post-bariatric surgery, proton pump inhibitor use, and gastrointestinal conditions that compromise tablet absorption. In December 2023, the FDA approved label updates to Tirosint-SOL making it the first levothyroxine therapy without a labeled drug interaction with proton pump inhibitors and the first that can be administered 15 minutes before breakfast rather than 30–60 minutes. Stock both forms if your practice serves bariatric, GI, transplant, or PPI-dependent patients.

Unithroid (Lannett / Jerome Stevens Pharmaceuticals)

Unithroid is manufactured by Jerome Stevens Pharmaceuticals and distributed by Lannett Company. Lannett filed for Chapter 11 bankruptcy in May 2023 and emerged in June 2023 as a private company after eliminating substantial debt. As of late 2025, Lannett continues to operate and distribute Unithroid. It occupies the lower-cost end of the branded levothyroxine market, making it a useful alternative when payer considerations favor a branded product at a price point below Synthroid.

Multi-Manufacturer Sourcing Strategy for Levothyroxine Procurement

The central procurement lesson of the 2024 Viatris recall is structural: any facility that depended on a single generic manufacturer for levothyroxine absorbed the full impact of that recall. Facilities that maintained multi-manufacturer sourcing routed around the disruption.

The current standard for levothyroxine procurement resilience is a four-tier sourcing structure:

Primary generic: Designate one preferred generic manufacturer based on current availability, FDA approval status, patient acceptance, and supply consistency. Document the rationale; review the designation quarterly.
Secondary generic: Maintain a second manufacturer’s supply at 30–50% of primary par level at the top three velocity strengths. This is the backstop for any single-manufacturer recall, quality hold, or facility disruption.
Branded bridge: Maintain at minimum a 14-day supply of Synthroid at the top three velocity strengths (50, 75, 100 mcg). Patients who cannot tolerate manufacturer substitution can be bridged on brand while generic supply is restored.
Specialty alternative: Stock Tirosint capsules and Tirosint-SOL for patients with documented absorption concerns. Lower volume but high clinical priority; do not allow these to stock out.

The procurement question to require of any distributor is: “For each generic manufacturer you source levothyroxine from, can you provide the current and projected supply status, the lot history for the past 90 days, DSCSA chain-of-custody documentation, and estimated availability for the next 60 days — on a single purchase order?” A distributor that cannot answer this question with document-backed responses is not equipped for current levothyroxine market conditions.

Par Levels by Practice Type

Par levels for levothyroxine should be built from actual patient panel data. The frameworks below are starting points. Calibrate to your prescribing volume and strength mix.

Worked Example: Independent Community Pharmacy (500 Active Levothyroxine Patients)

Assume dispensing history shows 500 patients, with 60% on 50, 75, or 100 mcg and the remainder distributed across other strengths. Average days supply per fill: 30 days. Average fills per patient per month: 1.

30-day par for 75 mcg (primary): 500 patients × 30% on this strength = 150 patients × 1 fill × 30-day supply = 4,500 tablets. Add 20% shortage buffer = 5,400 tablets from primary manufacturer.
Secondary manufacturer par (75 mcg): 30–50% of primary = 1,600–2,700 tablets.
Reorder trigger: When primary drops below 14 days of remaining supply (~2,100 tablets); secondary trigger at 21 days remaining.
Branded bridge (Synthroid 75 mcg): 14-day supply for the 10% of patients who are brand-stabilized = 150 tablets minimum.

Apply this calculation across each of your top six velocity strengths. The quarterly audit question is whether your per-strength par still matches your current patient mix — panel composition shifts as new patients are onboarded and titrations complete.

Retail or Independent Community Pharmacy

30-day par = 90-day historical dispensing volume ÷ 3, plus 20% shortage buffer
Stock the top six velocity strengths (typically 25, 50, 75, 100, 112, 125 mcg) at full par from the primary manufacturer
Stock the top three velocity strengths (50, 75, 100 mcg) at 30–50% par from a secondary manufacturer
Reorder trigger: 14 days remaining on primary; 21 days remaining on secondary
Maintain a minimum branded bridge supply of Synthroid at the top three velocity strengths

Endocrinology Specialty Practice

Stock all 12 strengths — specialty prescribing patterns require the full range
Higher per-patient volumes; prefer 100-count bottles over smaller blister packs for high-velocity strengths
Stock Tirosint capsules and Tirosint-SOL at a minimum 14-day par
Build secondary manufacturer coverage at parity with primary for the top six velocity strengths

Primary Care or Family Medicine

Narrower strength mix — the top six strengths typically cover 80–85% of dispensing
Secondary manufacturer at 30% par on the top three velocity strengths
Branded bridge limited to Synthroid 50, 75, 100 mcg

Specialty Pharmacy Serving Thyroid Cancer Surveillance

High-dose strengths (200, 300 mcg) move at meaningfully higher velocity than at a primary care pharmacy
Tirosint-SOL demand is elevated for post-thyroidectomy patients with absorption variability
Multi-manufacturer sourcing is non-negotiable given patient acuity — TSH suppression targets leave no margin for potency variation

Infusion Center or Hospital Outpatient Pharmacy

Lower direct dispensing volume but high clinical importance during inpatient-to-outpatient transitions
Coordinate with the discharge pharmacy team on manufacturer continuity to prevent post-discharge titration disruption

DSCSA Compliance and Levothyroxine Procurement

Levothyroxine sodium is a DSCSA-regulated prescription pharmaceutical. The DSCSA stabilization period ended August 27, 2025, and full electronic, package-level traceability enforcement began on a phased schedule. Manufacturers and wholesale distributors are under active enforcement. Large dispensers (26 or more licensed staff) were required to comply as of November 27, 2025. Smaller dispensers (25 or fewer) have a compliance deadline of November 27, 2026.

The Viatris recall illustrated how DSCSA traceability works in practice: pharmacies that maintained complete Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) records were able to identify affected lots quickly, process returns through validated channels, and document patient impact. Pharmacies that did not had to reconstruct records retroactively under time pressure.

DSCSA procurement checklist for levothyroxine sourcing:

Distributor holds active state wholesale pharmaceutical distribution licenses for your state — verify before every new relationship
Distributor provides TI, TH, and TS documentation for every levothyroxine shipment
Distributor’s DSCSA records are interoperable with your pharmacy management or EHR system for lot tracing
Distributor can identify which manufacturer supplied which lot on every reorder
Your facility has a documented recall response protocol that triggers when FDA publishes a Class I or Class II recall on any levothyroxine lot in your inventory

State Pharmacy Board Considerations

State rules on NTI drug substitution are not uniform. Certain state pharmacy boards — North Carolina and Kentucky among them — have rules that either require prescriber notification before switching an NTI drug to a different manufacturer or restrict generic substitution for NTI drugs entirely. Confirm your state’s current rules before changing manufacturer mid-therapy on a stabilized levothyroxine patient. This is a compliance requirement in some jurisdictions, not only a clinical best practice.

What to Require From Your Levothyroxine Distributor

Price remains important, but for levothyroxine in 2026, supply transparency is the more critical criterion. The following are the minimum requirements a distributor should be able to meet:

Multi-manufacturer availability: Can the distributor supply from at least two independent generic manufacturers and all four major brand-name products (Synthroid, Levoxyl, Tirosint/Tirosint-SOL, Unithroid) on a single purchase order?
Supply status visibility: Can the distributor provide current and 60-day projected availability for each manufacturer source and each strength?
DSCSA chain of custody: Does every shipment come with TI/TH/TS documentation at the lot level? Are records accessible for audit purposes?
Lot-level manufacturer sourcing declaration: Can the distributor confirm which manufacturer’s facility produced each lot at the time of every reorder?
State licensure: Is the distributor licensed for wholesale distribution in every state where your patients receive shipments?
Recall response capability: In the event of a new recall, can the distributor identify affected lots in your recent order history, process documented returns, and source substitute manufacturer supply within a defined timeframe?

A distributor that cannot answer these questions with documentation is operating against the same supply constraints you face, without the transparency to help you navigate them.

How USA MedPremium Approaches Levothyroxine Procurement

USA MedPremium’s levothyroxine sourcing is structured around the procurement vulnerabilities described in this guide:

DSCSA-compliant chain of custody on every shipment — TI/TH/TS documentation at the lot level, with state wholesale distribution licenses available for verification
Multi-manufacturer generic sourcing across primary and secondary suppliers for the top velocity strengths
Branded supply across Synthroid (AbbVie), Levoxyl (Pfizer), Tirosint and Tirosint-SOL (IBSA Pharma), and Unithroid (Lannett/Jerome Stevens Pharmaceuticals)
Recall response protocols that include lot-level traceability and substitute-manufacturer coordination — tested against the lessons of the 2024 Viatris recall
Procurement specialists available to handle urgent reorders when patient needs cannot wait for standard order cycles

For a free procurement audit covering levothyroxine and the rest of your pharmacy formulary, send your last 90 days of dispensing history to your USA MedPremium representative. A specialist will return a multi-manufacturer sourcing plan within five business days.

Connect with an Expert!

Explore the catalog:

FAQ

Frequently Asked Questions

Related reading:

Sources & References

Disclosure: USA MedPremium is a licensed pharmaceutical distributor. This article is for informational purposes only and does not constitute medical advice. Clinical decisions regarding levothyroxine therapy and manufacturer substitution should be made by qualified healthcare providers. Manufacturer availability, FDA shortage and enforcement status, DSCSA deadlines, and state pharmacy board rules change frequently — verify current details against the primary source before acting.

Back to all articles